Christopher P. Price
Research Subjects
Research Interests
Christopher P. Price has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
Carol L Davey
Department of Clinical Biochemistry, St. Bartholomew’s and the Royal London School of Medicine & Dentistry, Turner Street, London E1 2AD, UK
2 shared publicationsDavid J Newman
Department of Clinical Biochemistry, St. Bartholomew's and the Royal London School of Medicine and Dentistry, Turner Street, London E1 2AD, UK. P.O. Box 6101, Newark, DE 19714-610
2 shared publications- David J Newman
South West Thames Institute for Renal Research, St Helier Hospital, Carshalton, Surrey, UK
2 shared publications William D Bedzyk
Dade Behring Incorporated, Glasgow Research Laboratory, Bldg. 700, P.O. Box 6101, Newark, DE 19714-6101
2 shared publicationsYemi Olabiran
Department of Clinical Biochemistry, St. Bartholomew’s and the Royal London School of Medicine and Dentistry, Turner Street, London E1 2AD, UK
2 shared publicationsAlan R Craig
Dade International, Glasgow Business Community, Newark, DE 19714-6101
1 shared publication
Latest Publications
- 26 November 2001
- Published by Elsevier in Clinica Chimica Acta
- Vol. 315 (1-2) , 1
Foreword to ‘Screening for Disease’
- 26 November 2001
- Published by Elsevier in Clinica Chimica Acta
- Vol. 315 (1-2) , 1
Foreword to ‘Screening for Disease’
- Open Access
- 1 August 2001
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 47 (8) , 1345-1346
Microarrays: The Reincarnation of Multiplexing in Laboratory Medicine, But Now More Relevant?
Multiplexing is a relatively new addition to the Oxford English Dictionary and in the encyclopedic version is defined as “the simultaneous transmission of several messages along a single channel of communication”. It is also a relatively new addition to the vocabulary of the clinical chemist, having been imported from the lexicon of the genomics, proteomics, and drug discovery scientists, but it is not a new concept for the clinical chemist who has been exposed to the use of so-called multichannel analyzers for many years, first continuous flow and then discrete analyzers. Some historians of automation might look back to the centrifugal analyzer as the first challenge to multichannel analysis, but there is now at least one example of this technology that provides a profile of analytes on a single sample (1). If these are indeed early examples of multiplexing analyzers, then they distinguish themselves—by today’s standards—by using large amounts of sample and reagents, by a choice of analytes that are not always clinically justified, and by an inability (with a few notable exceptions) to embrace immunoassay and other ligand-binding assay techniques for low-concentration analytes. However, the greatest legacy of the first era of multiplexing analysis is probably the perception that there is too much laboratory testing as well as numerous apocryphal stories of patients being investigated after the generation of an abnormal result, rather than for the presenting symptoms!
- 1 August 2001
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 47 (8) , 1345-1346
Open AccessMicroarrays: The Reincarnation of Multiplexing in Laboratory Medicine, But Now More Relevant?
Multiplexing is a relatively new addition to the Oxford English Dictionary and in the encyclopedic version is defined as “the simultaneous transmission of several messages along a single channel of communication”. It is also a relatively new addition to the vocabulary of the clinical chemist, having been imported from the lexicon of the genomics, proteomics, and drug discovery scientists, but it is not a new concept for the clinical chemist who has been exposed to the use of so-called multichannel analyzers for many years, first continuous flow and then discrete analyzers. Some historians of automation might look back to the centrifugal analyzer as the first challenge to multichannel analysis, but there is now at least one example of this technology that provides a profile of analytes on a single sample (1). If these are indeed early examples of multiplexing analyzers, then they distinguish themselves—by today’s standards—by using large amounts of sample and reagents, by a choice of analytes that are not always clinically justified, and by an inability (with a few notable exceptions) to embrace immunoassay and other ligand-binding assay techniques for low-concentration analytes. However, the greatest legacy of the first era of multiplexing analysis is probably the perception that there is too much laboratory testing as well as numerous apocryphal stories of patients being investigated after the generation of an abnormal result, rather than for the presenting symptoms!
- 1 June 2001
- Published by Elsevier in Clinics In Laboratory Medicine
- Vol. 21 (2) , 285-304
Point-of-Care Testing: Impact on Medical Outcomes
- 1 June 2001
- Published by Elsevier in Clinics In Laboratory Medicine
- Vol. 21 (2) , 285-304
Point-of-Care Testing: Impact on Medical Outcomes
- Open Access
- 1 May 2001
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 38 (3) , 188-216
Pre- and post-analytical factors that may influence use of serum prostate specific antigen and its isoforms in a screening programme for prostate cancer
- 1 May 2001
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 38 (3) , 188-216
Open AccessPre- and post-analytical factors that may influence use of serum prostate specific antigen and its isoforms in a screening programme for prostate cancer
- 1 March 2001
- Published by Elsevier in Trends in Biochemical Sciences
- Vol. 26 (3) , 204
Mission impossible?
- 1 March 2001
- Published by Elsevier in Trends in Biochemical Sciences
- Vol. 26 (3) , 204
Mission impossible?
- Open Access
- 1 August 2000
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 46 (8) , 1041-1050
Evidence-based Laboratory Medicine: Supporting Decision-Making
There is an implicit acceptance that an evidence-based culture underpins the practice of laboratory medicine, in part because it is perceived as the scientific foundation of medicine. However, several reviews of specific test procedures or technologies have shown that the evidence base is limited and in many cases flawed. One of the key deficiencies in the scientific literature on diagnostic tests often is the absence of an explicit statement of the clinical need, i.e., the clinical or operational question that the use of the test is seeking to answer. Several reviews of the literature on specific procedures have also demonstrated that the experimental methodology used is flawed with, in some cases, significant bias being introduced. Despite these limitations it is recognized that a more evidence-based approach will help in the education and training of health professionals, in the creation of a research agenda, in the production of guidelines, in the support of clinical decision-making, and in resource allocation. Furthermore, as knowledge and technologies continue to be developed, an evidence-based strategy will be critical to harnessing these developments.
- 1 August 2000
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 46 (8) , 1041-1050
Open AccessEvidence-based Laboratory Medicine: Supporting Decision-Making
There is an implicit acceptance that an evidence-based culture underpins the practice of laboratory medicine, in part because it is perceived as the scientific foundation of medicine. However, several reviews of specific test procedures or technologies have shown that the evidence base is limited and in many cases flawed. One of the key deficiencies in the scientific literature on diagnostic tests often is the absence of an explicit statement of the clinical need, i.e., the clinical or operational question that the use of the test is seeking to answer. Several reviews of the literature on specific procedures have also demonstrated that the experimental methodology used is flawed with, in some cases, significant bias being introduced. Despite these limitations it is recognized that a more evidence-based approach will help in the education and training of health professionals, in the creation of a research agenda, in the production of guidelines, in the support of clinical decision-making, and in resource allocation. Furthermore, as knowledge and technologies continue to be developed, an evidence-based strategy will be critical to harnessing these developments.
- 1 July 2000
- Published by Elsevier in Clinica Chimica Acta
- Vol. 297 (1-2) , 55-66
Developments in the assessment of glomerular filtration rate
- 1 July 2000
- Published by Elsevier in Clinica Chimica Acta
- Vol. 297 (1-2) , 55-66
Developments in the assessment of glomerular filtration rate
- 1 November 1999
- Published by Taylor & Francis in Journal of Immunoassay
- Vol. 20 (4) , 253-273
Evaluation of a new Troponin I Method on the Bayer Immuno 1™ Immunoassay Analyser
We have evaluated the analytical and clinical performance of an automated immunoassay for serum cardiac troponin I (Bayer Immuno 1™, Bayer Diagnostics, Tarrytown, NY). the between batch imprecision was found to be between 1.2 and 3.2% over the concentration range 2.5-34.0 μg/L. the analytical range obtained from duplicate analysis of patient samples and defined as a coefficient of variation of 10% or less was 0.3 - 200 μg/L. the detection limit was found to be less than 0.1 μg/L. A method comparison with the Dade Stratus method (Dade Behring, Wilmington, DE) yielded regression statistics with a slope of 0.705 and an intercept of -0.260. an analysis of samples from 40 patients with renal failure demonstrated six with detectable levels of troponin I (0.2-1.9 μg/L). Samples from patients with paraproteinaemia did not demonstrate detectable troponin I (from n = 30); however, two patients with elevated rheumatoid factor titers (from n = 20) demonstrated a detectable amount of troponin I (0.1 and 0.2 μg/L). in a study of 100 patients admitted with acute chest pain and a diagnosis of unstable angina, 6 were subsequently diagnosed as having suffered a myocardial infarction. on admission the sensitivity and specificity of the troponin I results were 26.7% and 94.7%, respectively, moving to 100% and 83% 12 hours after admission.
- 1 November 1999
- Published by Taylor & Francis in Journal of Immunoassay
- Vol. 20 (4) , 253-273
Evaluation of a new Troponin I Method on the Bayer Immuno 1™ Immunoassay Analyser
We have evaluated the analytical and clinical performance of an automated immunoassay for serum cardiac troponin I (Bayer Immuno 1™, Bayer Diagnostics, Tarrytown, NY). the between batch imprecision was found to be between 1.2 and 3.2% over the concentration range 2.5-34.0 μg/L. the analytical range obtained from duplicate analysis of patient samples and defined as a coefficient of variation of 10% or less was 0.3 - 200 μg/L. the detection limit was found to be less than 0.1 μg/L. A method comparison with the Dade Stratus method (Dade Behring, Wilmington, DE) yielded regression statistics with a slope of 0.705 and an intercept of -0.260. an analysis of samples from 40 patients with renal failure demonstrated six with detectable levels of troponin I (0.2-1.9 μg/L). Samples from patients with paraproteinaemia did not demonstrate detectable troponin I (from n = 30); however, two patients with elevated rheumatoid factor titers (from n = 20) demonstrated a detectable amount of troponin I (0.1 and 0.2 μg/L). in a study of 100 patients admitted with acute chest pain and a diagnosis of unstable angina, 6 were subsequently diagnosed as having suffered a myocardial infarction. on admission the sensitivity and specificity of the troponin I results were 26.7% and 94.7%, respectively, moving to 100% and 83% 12 hours after admission.
- Open Access
- 1 June 1999
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 45 (6) , 822-828
Impact of Antibody Specificity and Calibration Material on the Measure of Agreement between Methods for Cardiac Troponin I
Background: Available assays for cardiac troponin I (cTnI) yield numerically different results. The aim of this study was to compare patient values obtained from four cTnI immunoassays. Methods: We studied the Stratus® II assay, the Opus® II assay, the Access® assay, and a research-only cTnI heterogeneous immunoassay that uses the Dade Behring aca® plus immunoassay system equipped with two new noncommercial monoclonal antibodies. Because the aca plus cTnI assay is for research only, we first evaluated and analytically validated it for serum and citrated plasma. Initially, each method was calibrated using the method-specific calibrator supplied by each manufacturer; however, the aca plus cTnI assay was calibrated using patient serum pools containing cTnI and selected on the basis of increased creatine kinase MB isoenzyme and with values assigned by use of the Stratus cTnI assay. For method comparisons, individual patient sample cTnI values were determined and compared with the Stratus II assay. Results: Passing and Bablock regression analysis yielded slopes of 1.44 (r = 0.96; n = 72) for the Opus II vs Stratus II assays; 0.07 (r = 0.91; n = 72) for the Access vs Stratus II assays; and 0.90 (r = 0.91, n = 72) for the aca plus vs Stratus II assays. The recalibration of each method with a Stratus II-assigned serum pool improved, but did not entirely eliminate, the slope differences between the different assays (range, 1.00–1.16). The observed scatter in the correlation curves remained. Conclusion: There is a need to further explore the specificities of these assays with respect to the different circulating forms of cTnI.
- 1 June 1999
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 45 (6) , 822-828
Open AccessImpact of Antibody Specificity and Calibration Material on the Measure of Agreement between Methods for Cardiac Troponin I
Background: Available assays for cardiac troponin I (cTnI) yield numerically different results. The aim of this study was to compare patient values obtained from four cTnI immunoassays. Methods: We studied the Stratus® II assay, the Opus® II assay, the Access® assay, and a research-only cTnI heterogeneous immunoassay that uses the Dade Behring aca® plus immunoassay system equipped with two new noncommercial monoclonal antibodies. Because the aca plus cTnI assay is for research only, we first evaluated and analytically validated it for serum and citrated plasma. Initially, each method was calibrated using the method-specific calibrator supplied by each manufacturer; however, the aca plus cTnI assay was calibrated using patient serum pools containing cTnI and selected on the basis of increased creatine kinase MB isoenzyme and with values assigned by use of the Stratus cTnI assay. For method comparisons, individual patient sample cTnI values were determined and compared with the Stratus II assay. Results: Passing and Bablock regression analysis yielded slopes of 1.44 (r = 0.96; n = 72) for the Opus II vs Stratus II assays; 0.07 (r = 0.91; n = 72) for the Access vs Stratus II assays; and 0.90 (r = 0.91, n = 72) for the aca plus vs Stratus II assays. The recalibration of each method with a Stratus II-assigned serum pool improved, but did not entirely eliminate, the slope differences between the different assays (range, 1.00–1.16). The observed scatter in the correlation curves remained. Conclusion: There is a need to further explore the specificities of these assays with respect to the different circulating forms of cTnI.
- 1 June 1999
- Vol. 18 (5) , 8
Health technology assessment.